Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Prostate Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 BMC Urol
1 Br J Cancer
1 Cancer
1 Cancer Res
3 Eur Urol
1 J Natl Cancer Inst
1 J Nucl Med
1 J Urol
2 Lancet Oncol
1 N Engl J Med
1 Nat Rev Urol
2 PLoS One
2 Prostate
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    AJR Am J Roentgenol

    Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
    AJR Am J Roentgenol. 2017;209:277-288.
    PubMed     Text format     Abstract available

  2. PURYSKO AS, Bittencourt LK, Bullen JA, Mostardeiro TR, et al
    Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate.
    AJR Am J Roentgenol. 2017 Jun 1:1-7. doi: 10.2214/AJR.16.17289.
    PubMed     Text format     Abstract available

    BMC Urol

  3. CAGNEY DN, Dunne M, O'Shea C, Finn M, et al
    Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.
    BMC Urol. 2017;17:60.
    PubMed     Text format     Abstract available

    Br J Cancer

  4. LOPHATANANON A, Stewart-Brown S, Kote-Jarai Z, Olama AAA, et al
    Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Active surveillance helps prostate cancer patients keep quality of life, findings show.
    Cancer. 2017;123:2997.
    PubMed     Text format    

    Cancer Res

  6. YIN Y, Li R, Xu K, Ding S, et al
    Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
    Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
    PubMed     Text format     Abstract available

    Eur Urol

  7. AGGARWAL R, Vigneron DB, Kurhanewicz J
    Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.
    Eur Urol. 2017 Jul 29. pii: S0302-2838(17)30651.
    PubMed     Text format    

  8. AGGARWAL A, Lewis D, Charman SC, Mason M, et al
    Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition.
    Eur Urol. 2017 Jul 28. pii: S0302-2838(17)30601.
    PubMed     Text format     Abstract available

  9. LARDAS M, Liew M, van den Bergh RC, De Santis M, et al
    Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
    Eur Urol. 2017 Jul 27. pii: S0302-2838(17)30535.
    PubMed     Text format     Abstract available

    J Natl Cancer Inst

  10. GAO X, Li LY, Rassler J, Pang J, et al
    Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available

    J Nucl Med

  11. WOYTHAL N, Arsenic R, Kempkensteffen C, Miller K, et al
    Immunohistochemical validation of PSMA-expression measured by 68Ga-PSMA PET/CT in primary prostate cancer.
    J Nucl Med. 2017 Aug 3. pii: jnumed.117.195172. doi: 10.2967/jnumed.117.195172.
    PubMed     Text format     Abstract available

    J Urol

  12. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

    Lancet Oncol

  13. SAAD F
    Androgen deprivation in prostate cancer: first do no harm.
    Lancet Oncol. 2017 Jul 28. pii: S1470-2045(17)30573.
    PubMed     Text format    

  14. DUCHESNE GM, Woo HH, King M, Bowe SJ, et al
    Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Lancet Oncol. 2017 Jul 28. pii: S1470-2045(17)30426.
    PubMed     Text format     Abstract available

    N Engl J Med

  15. HAYMART MR, Miller DC, Hawley ST
    Active Surveillance for Low-Risk Cancers - A Viable Solution to Overtreatment?
    N Engl J Med. 2017;377:203-206.
    PubMed     Text format    

    Nat Rev Urol

  16. STONE L
    Prostate cancer: A weighty issue: changes in chromatin regulation.
    Nat Rev Urol. 2017 Aug 1. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

    PLoS One

  17. ZHANG Y, Su X, Kong Z, Fu F, et al
    An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation.
    PLoS One. 2017;12:e0182305.
    PubMed     Text format     Abstract available

  18. ENDT K, Goepfert J, Omlin A, Athanasiou A, et al
    Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
    PLoS One. 2017;12:e0181557.
    PubMed     Text format     Abstract available


  19. HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
    The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
    PubMed     Text format     Abstract available

  20. VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
    Epigenetic risk score improves prostate cancer risk assessment.
    Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
    PubMed     Text format     Abstract available


  21. ZACHO HD, Petersen LJ
    Reply by the authors to the Editorial on: Zacho HD, Gade M, Mortensen JC, Bertelsen H, Boldsen SK, Petersen LJ. Bone scan index is an independent predictor for time to castration resistant prostate cancer in newly diagnosed prostate cancer: A prospect
    Urology. 2017 Jul 26. pii: S0090-4295(17)30760.
    PubMed     Text format    

  22. ZACHO HD, Gade M, Mortensen JC, Bertelsen H, et al
    Bone Scan Index is an Independent Predictor for Time to Castration-Resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: a Prospective Study.
    Urology. 2017 Jul 28. pii: S0090-4295(17)30759.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.